Free press releases distribution network?

Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Genetic Testing of Embryos Offers Acquisition Targets for Entrants in the U.S. Preimplantation Genetic Diagnosis Market Observes Frost & Sullivan - As the preimplantation genetic diagnosis (PGD) market is at a very early stage, the virtually untapped market harbors several targets for strategic acquisition
Genetic Testing of Embryos Offers Acquisition Targets for Entrants in the U.S. Preimplantation Genetic Diagnosis Market Observes Frost & Sullivan

 

PRZOOM - /newswire/ - Mountain View, CA, United States, 2011/03/23 - As the preimplantation genetic diagnosis (PGD) market is at a very early stage, the virtually untapped market harbors several targets for strategic acquisition.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

This market also offers new applications for advanced genomic technologies like Array CGH.

New analysis from Frost & Sullivan (drugdiscovery.frost.com), U.S. Preimplantation Genetic Diagnosis Market, finds that the market earned revenues of $23.1 million in 2010 and estimates this to reach $33 million in 2017.

If you are interested in more information on this study, please send an email to Britni Myers, Corporate Communications, at britni.myers[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country.

Assisted Reproductive Technology (ART) procedures and associated services, such as genetic testing of embryos produced from an ART cycle, will be in high demand as the number of women delaying motherhood is increasing. Couples that use in vitro fertilization (IVF) to become pregnant have a unique opportunity to assess aneuploidy or genetic mutations before embryos are implanted.

The ability to screen or diagnose genetic abnormalities as early as possible is pertinent to couples that have experienced recurring pregnancy loss by aneuploidy and are seeking treatment with ART. PGD screening of embryos for aneuploidy will be a major growth area as approximately half of the cases of embryonic loss within ART are associated with aneuploidy.

PGD is effective in detecting chromosomal and single-gene disorders with more than 99 percent diagnostic accuracy. The highly reliable test results are likely to drive an infertility medical professional or PGD genetic counselor to recommend the procedure.

"The success of ongoing clinical trials for broadening the scope of PGD testing of embryos beyond high-risk indications will go a long way in developing the market," said Frost & Sullivan industry analyst Winny Tan. "Without an indication that broadly reinforces the benefit from PGD, the market will remain a niche one."

Patient access to PGD will be limited until more PGD services experience reimbursement. The dynamics of the infertility markets and the high costs of IVF ultimately dictate the PGD market's characteristics. A reduction in IVF cycles can dampen the PGD market. However, greater market saturation achieved by expanding PGD services will promote overall growth in the future.

The current low market saturation indicates just how important effective customer marketing is. PGD market participants can compete more aggressively by targeting all customer segments of IVF, including key groups like infertility clinics and infertility patients.

"PGD labs should work closely with the medical staff at the IVF clinics that they serve," said Tan. "This trained staff of infertility experts, reproductive health physicians and PGD genetic counselors interface directly with IVF patients and are in the best position to advise or endorse PGD testing."

U.S. Preimplantation Genetic Diagnosis Market is part of the Clinical Diagnostics Growth Partnership Services program, which also includes research in the following markets: U.S. Inherited Disease Molecular Diagnostics Market, European Market for Foetal and Neonatal Monitoring Equipment Market, Advances in Fetal and Neonatal Diagnostics and Monitoring and U.S. Genetic Diagnostics Market. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.

U.S. Preimplantation Genetic Diagnosis Market / N8A4

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Genetic Testing of Embryos Offers Acquisition Targets for Entrants in the U.S. Preimplantation Genetic Diagnosis Market Observes Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Britni Myers 
210-477-8481 britni.myers[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  S&A Capital Partner Ltd

Visit  NAKIVO, Inc.







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today